An 800mg dose of the therapy twice a day was selected for the Phase IIa clinical trial. Credit: Hal Gatewood on Unsplash.

Ascletis Pharma has received approval from the US Food and Drug Administration (FDA) to conduct a Phase IIa clinical trial of ASC10 for the treatment of respiratory syncytial virus (RSV) infection.

The placebo-controlled, double-blind, randomised Phase IIa trial has been designed for assessing the tolerability, pharmacokinetics, antiviral activity, and safety of ASC10 tablets in mild or moderate RSV infection patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

An ASC10 800mg dose twice a day was selected for the trial, based on available data.

The oral double prodrug ASC10 is quickly and completely converted in vivo into the active metabolite ASC10-A, also called as β-D-N4-hydroxycytidine (NHC) or EIDD-1931, following oral administration.

In preclinical research, it was found that ASC10-A (NHC) is a potent inhibitor, with 0.51 to 0.6 uM EC50 against two RSV clinical isolates in HEp-2 cells using in vitro infection assay.

ASC10-A (NHC) was also found to be efficacious in a mouse RSV infection model in this research.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ascletis founder, chairman and CEO Dr Jinzi Wu said: “RSV poses a persistent threat to infants and the elderly population, and so far there is no effective drug available worldwide.

“We are glad that ASC10 has obtained the US FDA approval to conduct a Phase IIa study to treat RSV infection in patients, which is a new milestone of Ascletis’ research and development (R&D) in treatment for viral diseases.

“Preclinical research showed that ASC10-A is a potent inhibitor against RSV both in vitro and in vivo, and we will accelerate the Phase IIa clinical study to benefit patients worldwide.”

The United States Patent and Trademark Office (USPTO) has granted a patent for ASC10 and its derivatives, as well as their uses for the treatment of multiple virus infections including the monkeypox virus, RSV, and SARS-CoV-2.